Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs

Reboxetine is a specific norepinephrine transporter (NET) inhibitor and has been marketed in several countries as a racemic mixture of the (R,R) and (S,S) enantiomers for the treatment of depression. Its methyl analog (methylreboxetine, MRB) has been shown to be more potent than reboxetine itself. We developed a nine-step synthetic procedure to prepare the normethyl precursor, which was used to synthesize [C-11]O-methylreboxetine ([C-11]MRB). We also developed a convenient resolution method using a chiral HPLC column to resolve the racemic precursor to obtain enantiomerically pure individual precursors that lead to the individual enantiomers (R,R)-[C-11]MRB and (S,S)-[C-11]MRB. Here we report an evaluation of the racemate and individual enantiomers of [C-11]MRB as radioligands for PET imaging studies of NET systems in baboons both in brain and in peripheral organs. The relative regional distribution of the radioactivity after injection of [C-11]MRB in baboon brain is consistent with the known distribution of NET. For a NET-poor region such as striatum, there were no significant changes in the striatal uptakes with and without the nisoxetine pretreatment. In contrast, a significant blocking effect was observed in NET-rich regions such as thalamus and cerebellum after injection of racemic [C-11]MRB, with an even more dramatic effect after injection of (S,S)-[C-11]MRB. These results, along with the fact that there was no regional specificity and no blocking effect by nisoxetine for (R,R)-[C-11]MRB, suggest the enantioselectivity of MRB in vivo, consistent with previous in vitro and in vivo studies in rodents. PET studies of baboon torso revealed a blocking effect by desipramine only in the heart, a NET-rich organ, after injection of (S,S)-[C-11]MRB, but not the (R,R)-isomer. These studies demonstrate that the use of (S,S)-[C-11]MRB would allow a better understanding of the role that NET plays in living systems. (C) 2003 Wiley-Liss, Inc.